THE EVALUATION OF ANTI-TUMOR PROPERTIES OF B. SUBTILIS IMV B-7724 LECTIN IN VIVO STUDIES
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine, Kyiv, Ukraine
Aim: to investigate antitumor efficacy of lectin produced by B. subtilis IMV B-7724 on Ehrlich adenocarcinoma and Lewis lung carcinoma in vivo. Object and methods: the studies were performed on C57Bl/6J (n = 20) and Balb/c (n = 20) mice. In the investigation, the two experimental tumors were used: Ehrlich adenocarcinoma (EAC) and Lewis lung carcinoma (LLC). Starting from day 2 after the tumor cells transplantation, B. subtilis IMV B-7724 lectin was administered (s/c, 1 mg/kg of body weight, every other day, a total course consisted of 10 injections). The frequency of tumor development after the transplantation (%), the latent period of tumor appearance, the tumor volume (mm3), and the survival of the tumor-bearing animals were under evaluation. The statistical analysis of the results was performed according to the generally accepted methods of variation statistics. Results: The administration of bacterial lectin to mice bearing either EAC or LLC helped to slow the growth of experimental tumors and prolonged the survival time of tumor-bearing animals. More pronounced antitumor activity of the lectin was observed in mice bearing EAC. The index of tumor growth inhibition in this group of animals reached 53.2 ± 1.4%. In the mice bearing LLC, the administration of bacterial lectin showed a tendency to slow down the metastatization: the index of metastatization inhibition was 36.0 ± 4.5%. In the EAC-bearing mice, the course of 10-times lectin administration resulted in a statistically significant increase in survival time of 1.8 times comparing with the untreated control, p <0.05. When LLC tumor was used as an experimental model, the positive effect of B. subtilis IMV B-7724 lectin on the survival time of the tumor-bearing animals was expressed to a much lesser extent. The index of tumor growth inhibition reached only 18.2 ± 1.8%; the survival time increased by 33.3%. Conclusion: the antitumor efficacy of B. subtilis IMV B-7724 lectin was demonstrated in the animals bearing experimental tumors. Considering the standard indexes of tumor growth evaluation, the lectin application was more effective in non-metastatic solid Ehrlich adenocarcinoma.